LED Medical Diagnostics, Inc. (TSX-V: LMD), announced promising results of a study, titled "Fluorescence Visualization-Guided Surgery for Early-Stage Oral Cancer,” have been published in the Journal of the American Medical Association - Otolaryngology - Head and Neck Surgery.
The study, a retrospective, case-control observational study that was conducted on 246 patients from September 1, 2004, to August 31, 2009, showed a significant reduction in the rate of local recurrence of early-stage squamous cell carcinoma and high-grade precancerous lesions in patients where VELscope tissue fluorescence visualization was used to assist in determining the surgical margin for excision, compared to those patients where conventional methods were used.
"The results of this important clinical study will be of great interest to oral cancer patients and practitioners alike," said Dr. David Gane, CEO of LED Medical. "It adds to the growing body of peer reviewed literature that corroborates the use VELscope as an effective adjunct in oral cancer treatment, while further supporting its use in concert with a comprehensive oral examination to screen for the presence of oral cancers and pre cancers."
LED Medical provides dentists and oral practitioners with advanced diagnostic imaging products through its subsidiaries, LED Dental Inc. and LED Dental Ltd. The distinctive blue-spectrum light of the VELscope Vx Enhanced Oral Assessment System causes the soft tissues of the mouth to naturally fluoresce. Healthy tissues fluoresce in distinct patterns that are visibly disrupted by trauma or disease, such as neoplastic lesions, chemical irritation, and side effects from medication, thermal damage, and fungal, viral or bacterial infections.
Early detection is critical in the more than 40,000 new cases of oral cancer diagnosed in the United States every year. The company’s FDA approved VELscope® Vx Enhanced Oral Assessment System is utilized for this purpose, and is currently used by 12,000 dental practitioners in 23 countries.
"This is really a revolutionary way for surgeons to visualize a diseased region," stated Dr. Catherine Poh, principal investigator and Provincial Oral Medicine Leader for Oral Oncology at the BC Cancer Agency. "We are now working with head and neck surgeons across Canada to conduct a multi-center trial that will convince the world to change practice and improve the treatment of oral cancer."
The publication of the company’s groundbreaking results follows a number of positive highlights for the company, including:
- Completing the second tranche of debenture financing.
- Submitting LOI to acquire profitable technology company.
Furthermore, earlier this month, the company announced their preliminary unaudited revenue for its fiscal year ended December 31, 2015 of approximately US $12.5 million, representing approximately 40% revenue growth over the prior fiscal year.
The quality of health care in the dentistry and oral health care industries have improved dramatically due to the rapid advancement of technology. Through their innovative and proven effective VELscope®, LED Medical is positioned to greatly expand their reach. “I expect the results of this landmark study to accelerate the penetration of the VELscope into dental offices globally,” said Gane. “Oral health care providers should be comforted to know that the VELscope technology that they use daily on their patients is the same technology being used by surgeons to help treat early-stage oral cancers.”
For more information about LED Medical, visit www.leddental.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of
1933 and in the interest of full disclosure, we call the reader's
attention to the fact that Equities.com, Inc. may be compensated by the
companies profiled in the Spotlight Companies section. The purpose of
these profiles is to provide awareness of these companies to investors
in the micro, small-cap and growth equity community and should not in
any way come across as a recommendation to buy, sell or hold these
securities. Equities.com is not a registered broker, broker dealer,
investment advisor, analyst, investment banker or underwriter. All
profiles are based on information that is available to the public. The
information contained herein should not be considered to be
all-inclusive and is not guaranteed by Equities.com to be free from
misstatement or errors. Readers are reminded to do their own due
diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer